Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes
Publisher
Springer New York
Reference112 articles.
1. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2006:108(2):711–717.
2. Carroll WL, Bhojwani D, Min DJ, et al. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 2006:46(5):570–578.
3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008:112(1):45–52.
4. Finn R. Medicare analysis suggests MDS is “severely underestimated.” Oncol Rep 2009(Spring): 21(1):37–38.
5. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007:109(8):1536–1542.